Eledon’s Tegoprubart Shows Sustained Kidney Function in Long-Term Transplant Trial
Event summary
- Eledon presented 24-month Phase 1b data for tegoprubart in kidney transplant patients at the American Society of Transplant Surgeons Winter Symposium on January 23, 2026.
- Mean eGFR increased from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months in eight patients.
- No episodes of biopsy-proven acute rejection, graft loss, death, new-onset diabetes mellitus, or de novo donor-specific antibody formation were reported.
- Tegoprubart, an anti-CD40L antibody, is being developed for kidney allograft transplantation, xenotransplantation, islet cell transplantation, and ALS.
The big picture
Eledon’s long-term data for tegoprubart reinforces its potential as a non-lymphocyte-depleting immunosuppressant, a critical advantage in transplant medicine where balancing efficacy and safety is paramount. The results position tegoprubart as a contender in a market dominated by calcineurin inhibitors, though scaling from small cohorts to broader approval remains a hurdle. The broader industry is watching immunomodulatory therapies closely, particularly those targeting CD40L, given its role in multiple autoimmune and transplant indications.
What we're watching
- Clinical Validation
- Whether the sustained eGFR improvements in a small cohort will translate to larger, controlled trials.
- Regulatory Pathway
- The pace at which Eledon can advance tegoprubart through Phase 2 and 3 trials given the positive long-term data.
- Competitive Positioning
- How Eledon differentiates tegoprubart in the crowded kidney transplant immunosuppression market.
Related topics